Generics Bulletin Q4 Results Preview: Sandoz, Pfizer, Dr Reddy’s, Wockhardt And Strides

Eyes will be on Sandoz and parent company Novartis this week after recent moves to shift Sandoz’ focus further towards complex generics and biosimilars. Meanwhile, Pfizer will announce its fourth-quarter results shortly after cutting funding for several of its biosimilars programs and Dr Reddy’s will reveal the impact of a ramp-up in US launches.